cellcentric.comCrawled Oct 24, 2026
CellCentric is developing inobrodib to improve cancer treatment outcomes, targeting multiple indications as a monotherapy or with existing therapies.
Oncologists at clinical trial sites determine eligibility for inobrodib trials; patients should consult their doctor for guidance.
Inobrodib has been tested in over 450 patients across tumor types, with ongoing focus on multiple myeloma.
Inobrodib is an oral small-molecule inhibitor that targets p300 and CBP by binding to their bromodomains, altering chromatin interactions and impacting cancer drivers like MYC and IRF4.
Randomized Phase II Dose-Optimization Study of Inobrodib in Combination with Pom+Dex in Relapsed/Refractory Multiple Myeloma
Tolerability and clinical activity of novel first-in-class oral agent, inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies
Updated Results from Randomized Phase II Dose Optimization Study of Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)
CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology.
Jason joined the Board of CellCentric in March 2017 and became Chair in January 2022.
The company is developing a p300/CBP inhibitor for treating multiple myeloma and other cancers.
CellCentric is built on the science of co-founder Azim Surani, Ph.D., of the Gurdon Institute, University of Cambridge. As a pioneer of cell fate control research, Dr. Surani discovered and described an inherited code, beyond DNA, that instructs cell function and fate. It quickly became clear that studying chromatin-related cell fate control mechanisms could yield many unexplored targets for new drug discovery.
CellCentric operates internationally with offices in the UK and US, along with multiple research and clinical collaborators and delivery contractors across the globe.
CellCentric is developing inobrodib, an oral p300/CBP inhibitor, for treating multiple myeloma and other cancers.
